Immunogenicity of Novel AAV Capsids for Retinal Gene Therapy

Objectives: AAV vectors are widely used in gene therapy, but the prevalence of neutralizing antibodies raised against AAV serotypes in the course of a natural infection, as well as innate and adaptive immune responses induced upon vector administration, is still considered an important limitation. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehrke, Miranda, Diedrichs-Möhring, Maria, Bogedein, Jacqueline, Büning, Hildegard, Michalakis, Stylianos, Wildner, Gerhild
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221425/
https://www.ncbi.nlm.nih.gov/pubmed/35741009
http://dx.doi.org/10.3390/cells11121881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221425/
https://www.ncbi.nlm.nih.gov/pubmed/35741009
http://dx.doi.org/10.3390/cells11121881

Ejemplares similares